Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590789873> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2590789873 endingPage "114" @default.
- W2590789873 startingPage "114" @default.
- W2590789873 abstract "114 Background: Adjuvant chemotherapy is proved to improve survival in gastric cancer by meta-analyses. However, no evidence showed the best regimen. We conducted a retrospective analysis to compare triplets with doublets in the adjuvant setting. Methods: We collected data from January 2004 to December 2008 from patients performed radical surgery and adjuvant chemotherapy. Doublets were defined as 5-FU 750 mg/m 2 (d1- 5) or capecitabine 1,000 mg/m 2 (d1-14) plus cisplatin 60 mg/m 2 (d1) or oxaliplatin 130 mg/m 2 (d1), while triplets had epirubicin 50 mg/m 2 (d1) added. Chemotherapy was initiated within 6 weeks after surgery, repeated every three weeks and planned for 6 cycles. Patients were followed up in the outpatient clinic until death or April 30, 2010. Cox proportional-hazard model and chi-square test were used to test statistical difference. Results: A total of 316 patients (210 in doublets, 106 in triplets) had a median follow-up time of 47 months. 77 patients died at the end of follow-up (3-year survival of 67.4%).Two groups were well balanced except age (median age of 57 in doublets, 51 in triplets, p < 0.001). All the patients tolerated well, with few grade 3/4 side effects (21.9% in doublets, 30.2% in triplets, p = 0.107). Two groups had similar disease-free survival (median DFS, 16 months vs. 23 months, p = 0.656) and overall survival (3-year survival rate, 59.6% vs. 64.8%, p = 0.293). Subgroup analysis showed the same benefit on survival between the two groups. Conclusions: Our study suggested doublets and triplets had the same efficacy as the adjuvant chemotherapy. Furthermore, doublets seem more cost-effective. [Table: see text] No significant financial relationships to disclose." @default.
- W2590789873 created "2017-03-03" @default.
- W2590789873 creator A5005977962 @default.
- W2590789873 creator A5040074001 @default.
- W2590789873 creator A5074842133 @default.
- W2590789873 creator A5081653175 @default.
- W2590789873 date "2011-02-01" @default.
- W2590789873 modified "2023-09-28" @default.
- W2590789873 title "Adjuvant chemotherapy for gastric cancer: Less drug, same efficacy." @default.
- W2590789873 doi "https://doi.org/10.1200/jco.2011.29.4_suppl.114" @default.
- W2590789873 hasPublicationYear "2011" @default.
- W2590789873 type Work @default.
- W2590789873 sameAs 2590789873 @default.
- W2590789873 citedByCount "0" @default.
- W2590789873 crossrefType "journal-article" @default.
- W2590789873 hasAuthorship W2590789873A5005977962 @default.
- W2590789873 hasAuthorship W2590789873A5040074001 @default.
- W2590789873 hasAuthorship W2590789873A5074842133 @default.
- W2590789873 hasAuthorship W2590789873A5081653175 @default.
- W2590789873 hasConcept C121608353 @default.
- W2590789873 hasConcept C126322002 @default.
- W2590789873 hasConcept C141071460 @default.
- W2590789873 hasConcept C167135981 @default.
- W2590789873 hasConcept C207103383 @default.
- W2590789873 hasConcept C2776694085 @default.
- W2590789873 hasConcept C2776755627 @default.
- W2590789873 hasConcept C2777909004 @default.
- W2590789873 hasConcept C2778239845 @default.
- W2590789873 hasConcept C2778336483 @default.
- W2590789873 hasConcept C2780835546 @default.
- W2590789873 hasConcept C2780962732 @default.
- W2590789873 hasConcept C2781413609 @default.
- W2590789873 hasConcept C44249647 @default.
- W2590789873 hasConcept C50382708 @default.
- W2590789873 hasConcept C526805850 @default.
- W2590789873 hasConcept C71924100 @default.
- W2590789873 hasConcept C90924648 @default.
- W2590789873 hasConceptScore W2590789873C121608353 @default.
- W2590789873 hasConceptScore W2590789873C126322002 @default.
- W2590789873 hasConceptScore W2590789873C141071460 @default.
- W2590789873 hasConceptScore W2590789873C167135981 @default.
- W2590789873 hasConceptScore W2590789873C207103383 @default.
- W2590789873 hasConceptScore W2590789873C2776694085 @default.
- W2590789873 hasConceptScore W2590789873C2776755627 @default.
- W2590789873 hasConceptScore W2590789873C2777909004 @default.
- W2590789873 hasConceptScore W2590789873C2778239845 @default.
- W2590789873 hasConceptScore W2590789873C2778336483 @default.
- W2590789873 hasConceptScore W2590789873C2780835546 @default.
- W2590789873 hasConceptScore W2590789873C2780962732 @default.
- W2590789873 hasConceptScore W2590789873C2781413609 @default.
- W2590789873 hasConceptScore W2590789873C44249647 @default.
- W2590789873 hasConceptScore W2590789873C50382708 @default.
- W2590789873 hasConceptScore W2590789873C526805850 @default.
- W2590789873 hasConceptScore W2590789873C71924100 @default.
- W2590789873 hasConceptScore W2590789873C90924648 @default.
- W2590789873 hasIssue "4_suppl" @default.
- W2590789873 hasLocation W25907898731 @default.
- W2590789873 hasOpenAccess W2590789873 @default.
- W2590789873 hasPrimaryLocation W25907898731 @default.
- W2590789873 hasRelatedWork W2002532865 @default.
- W2590789873 hasRelatedWork W2005899744 @default.
- W2590789873 hasRelatedWork W2019962863 @default.
- W2590789873 hasRelatedWork W2111494034 @default.
- W2590789873 hasRelatedWork W2239918529 @default.
- W2590789873 hasRelatedWork W2350465271 @default.
- W2590789873 hasRelatedWork W2418334170 @default.
- W2590789873 hasRelatedWork W2512672305 @default.
- W2590789873 hasRelatedWork W2944281980 @default.
- W2590789873 hasRelatedWork W3013662455 @default.
- W2590789873 hasVolume "29" @default.
- W2590789873 isParatext "false" @default.
- W2590789873 isRetracted "false" @default.
- W2590789873 magId "2590789873" @default.
- W2590789873 workType "article" @default.